(P082) Photoacoustic Imaging for Improved Intraoperative Visualization of Prostate Brachytherapy Seeds

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Photoacoustic imaging is a promising complement to ultrasound imaging for intraoperative brachytherapy seed visualization. Work is ongoing for eventual translation into human clinical trials.

Muyinatu Bell, PhD, Emad Boctor, PhD, Nathanael Kuo, PhD, Jin Kang, PhD, Danny Y. Song, MD; Johns Hopkins University

Purpose: Current ultrasound technology offers suboptimal intraoperative visualization of brachytherapy seeds. Photoacoustic imaging has the promise to enhance seed localization compared with standard ultrasound imaging. Photoacoustic imaging utilizes light transmitted into tissue; metallic seeds absorb the transmitted light, undergo thermoelastic expansion, and generate sound waves that are detected with a conventional transrectal ultrasound probe. Excellent seed contrast is expected in photoacoustic images, because the optical absorption of brachytherapy seeds is orders of magnitude larger than that of the surrounding tissue, and this difference is larger than the corresponding acoustic echo difference. We conducted an institutionally approved canine study to investigate the in vivo feasibility of intraoperative seed visualization with photoacoustic imaging.

Materials and Methods: Brachytherapy seeds, coated with black ink, were transperineally inserted into a live canine prostate. A transperineal, interstitial, fiberoptic light delivery method, coupled to a 1064-nm Nd:Yag laser, was used to emit laser into the prostate containing the seeds. The resulting acoustic waves were detected with a conventional transrectal ultrasound probe (Ultrasonix, BPL9-5/55, Richmond, BC, Canada) connected to a clinical ultrasound scanner (Ultrasonix Sonixtouch). Raw prebeam-formed photoacoustic data were collected with a Sonixdaq data acquisition unit that was connected to a probe port on the ultrasound scanner. Ultrasound and postoperative CT images of the implanted seeds were acquired and analyzed to confirm seed locations in the photoacoustic images.

Results: Multiple brachytherapy seeds were visualized within the in vivo prostate within American National Standards Institute (ANSI) laser safety limits for human exposure (100 mJ/cm2). Seeds that were difficult to localize in standard ultrasound images were more visible in coregistered photoacoustic images. the average seed contrast in the photoacoustic images was 20–30 Db for energy densities ranging from 8–84 mJ/cm2 when the short-lag spatial coherence beamformer was applied to the raw data. There was excellent agreement between photoacoustic, ultrasound, and CT image.

Conclusion: Photoacoustic imaging is a promising complement to ultrasound imaging for intraoperative brachytherapy seed visualization. Work is ongoing for eventual translation into human clinical trials.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Recent Videos
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Related Content